Free Clinical Trial Enrollment Revenue Calculator
How Much Enrollment Revenue Could Your Research Site Be Missing?
Estimate potentially unrealized screening and randomization revenue, along with coordinator-capacity cost, using your research site's own numbers.
- Free industry tool
- No patient information
- Uses your site's assumptions
- Results available immediately
The calculator produces modeled estimates, not guaranteed savings or enrollment outcomes.
Research — Tufts Center for the Study of Drug Development
Later-stage clinical trials are expensive to operate.
≈$40K/day
Researchers at the Tufts Center for the Study of Drug Development (Tufts CSDD) estimated the mean direct daily operating cost of Phase II and Phase III clinical trials combined at approximately $40,000.
Those are sponsor-level trial economics. Your site’s economics are different.
Use the calculator below to model your own screening, randomization, staffing, and site-budget assumptions.
Smith, DiMasi & Getz, “New Estimates on the Cost of a Delay Day in Drug Development”This sponsor-level estimate is not site revenue and does not mean every day of enrollment delay costs a research site $40,000.
The National Cost of Enrollment Leakage
Enrollment Gaps May Be Leaving Millions in Research-Site Revenue Unrealized
Modeled U.S. Research-Site Revenue Potentially Left Unrealized So Far This Year
Modeled U.S. research-site revenue potentially left unrealized so far this year under the selected scenario. Annual modeled revenue at risk: $136.3M. This is an assumption-driven planning model, not a measured national loss.
$136.3M in modeled annual research-site revenue at risk
This scenario estimates revenue that may never be generated when patient inquiries do not progress to attended screening visits and randomization.
This is the year-to-date portion of the selected $136.3M annual planning scenario.
This is an assumption-driven planning model, not a measured national loss. Actual revenue varies by protocol, site budget, enrollment performance, and direct delivery costs.
Missed Attended Screenings
Potential site screening payments may never be generated when patient inquiries do not progress to completed site-controlled screening visits.
Missed Randomizations
Randomization payments and later participant activity may never generate site revenue when screened participants do not progress.
Coordinator-Capacity Cost
Staff time may be consumed by unresolved inquiries, repeated contact attempts, incomplete follow-up, and avoidable rework.
Coordinator-capacity cost is not included in the $136.3M modeled revenue figure. It is calculated and displayed separately as an economic use of staff resources.
Per day
$373,516
Per hour
$15,563
Per minute
$259.39
Per second
$4.3231
Underlying Assumptions
Recruiting studies with U.S. locations
22,168
ClinicalTrials.gov snapshot, July 14, 2026
Estimated U.S. site relationships per study
3
Historical global median from industry-funded randomized trials. Not a current measured U.S. site average.
Site-protocol relationships affected
25%
User-adjustable planning percentage. Not a measured national rate.
Potentially unrealized attended screenings per affected relationship annually
12
Default planning scenario assumes one potentially unrealized attended screening per month. No direct national source is being applied.
Illustrative Net Contribution per Attended Screening
$350
Replace with expected collected screening revenue minus the direct cost of performing the visit. No established national screening-value benchmark is being applied.
Potentially unrealized randomizations per affected relationship annually
2
Default planning scenario assumes two potentially unrealized randomizations annually. No direct national performance rate is being applied.
Illustrative Additional Net Contribution per Randomization
$2,000
Replace with expected additional net site contribution after randomization, excluding screening value already counted. No established national randomization-value benchmark is being applied.
Source Status
The recruiting-study count is official ClinicalTrials.gov data. The estimated sites-per-study input is a historical research proxy. The affected percentage, screening volume, randomization volume, and financial contribution values are adjustable modeling assumptions, not published national averages.
Change the assumptions to explore a different national scenario. For a site-specific estimate, use the calculator with actual protocol budgets and recent enrollment performance.
ClinicalTrials.gov reports studies, not a complete count of active U.S. site-protocol relationships or their payment arrangements. The 22,168-study total includes multiple study types and funding arrangements and is not a count of commercially funded, randomized, screening-payment-based studies.
Site Calculator
Calculate Your Site's Estimate
Start with information available from recent enrollment reports and study budgets. Use a consistent protocol or portfolio scope throughout the estimate.
Your Personalized Estimate Will Appear Here
Enter your site information or load the illustrative example to calculate potentially unrealized revenue, coordinator-capacity cost, and modeled economic value.
Your calculator entries remain in your browser unless you choose to email the analysis. If you submit the form, your contact information, calculator inputs, and results are sent to Consent2Randomize and emailed to you. Do not enter patient names, medical information, referral records, eligibility information, or protected health information.
A clinical research site can estimate enrollment-related revenue opportunity by comparing current screening and randomization activity with a realistic attainable scenario, then applying the site's own net contribution per attended screening, additional net contribution per randomization, and fully loaded coordinator labor cost.
The Economic Problem
Where Enrollment Value Begins to Disappear
Research sites invest in startup, training, staffing, recruitment, and ongoing study activity before meaningful participant revenue is generated.
When inquiries remain unreached, preliminary information stays incomplete, or scheduled appointments are not attended, some of that investment may not progress into screening and randomization activity.
This calculator estimates selected parts of that economic difference. It does not assume every gap is caused by site workflow or that every modeled difference can be recovered.
The enrollment value sequence
Patient interest Successful contact Preliminary information completed Documented site handoff Appointment scheduled Appointment attended Site screening Randomization
The Problem in Detail
Where Enrollment Revenue Can Become Unrealized
Enrollment revenue rarely becomes unrealized at one single point. Patient interest may gradually stop progressing as it moves toward site-controlled screening and randomization.
A. Unreached patient inquiries
Advertising and referral activity have limited value when inquiries are not reached promptly or contact attempts are not managed consistently.
Potential effects
- Paid or referred patient interest does not progress
- Staff time is consumed by repeated unsuccessful attempts
- The inquiry remains unresolved
- Referral sources receive limited disposition visibility
B. Incomplete preliminary information
Incomplete early information may delay site review, create repeated clarification work, and leave referrals unresolved. This stage does not determine eligibility.
Potential effects
- Delayed or repeated site review
- Rework from incomplete or unclear records
- Referrals left unresolved
C. Scheduling and attendance gaps
A scheduled appointment does not create site value unless the person attends and the site can perform the relevant protocol-controlled activity.
Potential effects
- Underused appointment capacity
- Repeated scheduling work
- Delayed screening activity
- Lower progression from patient interest to completed site visits
D. Coordinator-capacity use
Early enrollment work competes with regulatory, participant-facing, data, safety, sponsor, and protocol responsibilities. Coordinator-capacity cost is the economic value of staff time used on incomplete or unproductive early enrollment activity. It is not necessarily an immediate reduction in payroll expense.
Potential effects
- Reduced capacity for clinical and regulatory work
- Longer follow-up cycles
- Less visibility into what remains open
E. Low study enrollment
A study may consume startup, training, contracting, regulatory, and maintenance resources without generating enough participant activity to offset those costs. Workflow improvement alone does not necessarily prevent study underperformance.
Potential effects
- Unrecovered startup and maintenance costs
- Sponsor or institutional financial pressure
- Potential for earlier study closure
The calculator measures selected parts of this problem. It does not calculate the complete financial effect of opening, maintaining, delaying, or closing a clinical study.
The Operating Solution
How Stronger Early Enrollment Operations Can Reduce the Gap
More patient interest does not automatically produce more completed screening visits. Research sites also need a consistent operating process for moving each inquiry toward the next appropriate site-controlled step.
Capture
Record each inquiry in a consistent workflow so patient interest does not remain scattered across disconnected inboxes, spreadsheets, messages, or referral lists.
Clarify
Collect permitted preliminary information, resolve nonclinical questions, and identify what remains incomplete before documented site review. This is not an eligibility decision.
Follow Up
Use defined contact attempts, response intervals, disposition categories, and next actions so unresolved inquiries do not simply disappear.
Prepare
Help people understand practical appointment details without conducting informed consent, interpreting the protocol clinically, or giving medical guidance.
Handoff
Provide the research site with organized documentation and a clear status so site personnel can perform their clinical and protocol-controlled responsibilities.
A stronger workflow does not guarantee enrollment. It improves the site's ability to see what happened, what remains unresolved, and where operational attention may be needed.
Learn more about the enrollment operations framework →The Service Boundary
Where Consent2Randomize Fits
When Post-Interest Enrollment Support is in scope, Consent2Randomize can support defined early enrollment operations after referral or patient interest and before site-controlled consent and screening.
Consent2Randomize can support
- Inquiry capture and organization
- Permitted preliminary information collection
- Nonclinical clarification
- Defined follow-up activity
- Status documentation
- Appointment coordination
- Attendance preparation
- Documented handoff to the research site
- Operational reporting on progression and unresolved work
The research site retains
- Clinical judgment
- Eligibility decisions
- Medical discussion
- Informed consent
- Protocol interpretation
- Screening procedures
- Randomization
- Investigator oversight
- Participant care
- Protocol oversight
The appropriate operating model depends on the protocol, existing site staff, referral volume, permitted activities, sponsor expectations, and the point at which current workflow performance begins to break down. Not every site needs outside support.
Review My Enrollment WorkflowC2R Analysis · National Context
Change the National Scenario
Select a scenario or enter custom assumptions to model how enrollment-related revenue opportunity could accumulate across U.S. site-protocol relationships. Changing the scenario here also updates the counter at the top of this page.
No complete national dataset directly measures research-site revenue left unrealized because of enrollment workflow gaps. The scenarios below combine official study counts with visible, adjustable assumptions.
Financial Inputs
The screening and randomization amounts are illustrative planning inputs. Replace them with protocol-specific net contribution values when available.
Annual Modeled Revenue at Risk
$136,333,200
Per day
$373,516
Per hour
$15,563
Per minute
$259.39
Per second
$4.3231
Affected site-protocol relationships: 16,626
National Coordinator-Capacity Model
Calculated separately from revenue at risk.
Annual Modeled Coordinator-Capacity Cost
$79,804,800
Combined modeled economic value including capacity cost
$216,138,000
Coordinator-capacity cost is not included in the revenue figure above. Combined value shows both categories together for comparison only.
ClinicalTrials.gov reports studies, not a complete count of active U.S. site-protocol relationships or the revenue terms associated with those relationships. The sites-per-study, affected-percentage, screening-contribution, and randomization-contribution values are modeling assumptions.
ClinicalTrials.gov reported 19,072 recruiting studies with U.S.-only locations and 3,096 recruiting studies with both U.S. and international locations as of July 14, 2026. The national model applies user-adjustable assumptions to the combined total of 22,168 studies.
The ClinicalTrials.gov total includes multiple study types and funding arrangements. It is not a count of commercially funded, randomized, or screening-payment-based research studies.
The estimated U.S. site relationships per study value is a scenario assumption. The cited historical research reported wide variation in the number and geographic distribution of sites across industry-sponsored trials.
The percentage of site-protocol relationships experiencing material revenue leakage is an illustrative assumption. It is not a measured national rate.
Screening and randomization contribution values are illustrative inputs. Actual research-site budgets vary by protocol, sponsor, therapeutic area, procedures, negotiated terms, and direct delivery costs.
The national model is designed to make assumptions inspectable, not to manufacture a precise national loss figure.
Methodology
How the Research Site Revenue Estimate Works
Potentially unrealized screening revenue
The modeled difference between current and attainable attended screening visits multiplied by the site's net contribution per attended screening.
Potentially unrealized randomization revenue
The modeled difference between current and attainable randomizations multiplied by the site's additional net contribution per randomized participant.
Coordinator-capacity cost
Hours used on incomplete or unproductive early enrollment work multiplied by the fully loaded hourly labor cost.
Net contribution
Collected or expected site revenue for an activity minus the direct cost of performing that activity.
Combined modeled economic value
Potentially unrealized screening revenue, potentially unrealized randomization revenue, and coordinator-capacity cost combined.
| Formula | Calculation |
|---|---|
| Additional attended screenings | max(attainable screenings - current screenings, 0) |
| Monthly screening revenue opportunity | additional screenings x net contribution per screening |
| Monthly randomization revenue opportunity | additional randomizations x additional net contribution per randomization |
| Monthly potentially unrealized revenue | screening revenue + randomization revenue |
| Monthly coordinator-capacity cost | unproductive hours x fully loaded hourly cost |
| Combined monthly modeled economic value | potentially unrealized revenue + coordinator-capacity cost |
| Annual values | monthly value x 12 |
These categories are not interchangeable. Coordinator-capacity cost is not necessarily a cash saving. Modeled revenue opportunity is not revenue already earned or guaranteed to be collected.
- Developed by
- Consent2Randomize
- Methodology reviewed
- August 6, 2026
- Model status
- Illustrative planning model, not externally validated
- Data handling
- Browser-based calculation unless the visitor voluntarily submits the email-analysis form
Research Behind the Calculator
Research Behind the Calculator
Source 1
ClinicalTrials.gov Trends and Charts
As of July 14, 2026, ClinicalTrials.gov listed 19,072 recruiting studies with U.S.-only locations and 3,096 recruiting studies with both U.S. and international locations. The count includes multiple study types and is not a count of active research sites.
Source 2
Industry-Sponsored Trial Site and Recruitment Metrics
A study of industry-sponsored phase III drug trials reported that the median number of registered sites increased from 43 in 2012 through 2015 to 64 in 2016 through 2019, while median participants enrolled per site declined from seven to six. This figure should not be applied to all current U.S. trials.
Source 3
Industry-Sponsored Clinical Research Site Distribution
A broad historical analysis of industry-sponsored clinical trials from 2006 through 2013 reported a median of three sites across all analyzed trials, with substantial variation by geographic scope. This was a historical and global analysis.
Source 4
The Prevalence and Economic Impact of Low-Enrolling Clinical Studies
At one academic medical center, 31.1% of terminated studies enrolled zero or one participant. The study estimated nearly $1 million in uncompensated institutional impact during FY2009. This was one academic medical center and is not a national rate or universal cost.
Source 5
Characteristics and Causes of Non-Accrued Clinical Research
At another academic medical institution, 17% of analyzed study closures reported zero enrollment. Reported causes included recruitment issues and insufficient study-dedicated resources. This was a single-institution study.
Source 6
Terminated Trials in the ClinicalTrials.gov Results Database
In a historical analysis of 7,646 trials with posted results, insufficient accrual accounted for 350 terminated trials and 39% of all terminated trials in the dataset. This 39% figure describes terminated trials in the dataset, not the percentage of all clinical trials that terminate from insufficient accrual.
Source 7
Developing an Investigator Site Budget for Clinical Trials
Research-site budgeting should account for screening, staff time, participant visits, regulatory work, documentation, and other direct and hidden costs. The publication includes a protocol-specific example rather than a universal reimbursement amount.
Source 8
Performance-Based Clinical Trial Site Funding
One large NIH-supported multisite trial used a hybrid funding model in which approximately 60% of the site budget was tied to successful enrollment and completed follow-up activity. This was one trial-specific funding model.
Source 9
Recruitment Effort and Costs from a Multi-Center Randomized Controlled Trial
One multisite trial documented substantial contact volume, staff time, and recruitment costs to enroll participants. That trial's cost per enrollee should not be applied to every research site.
Source 10
Clinical Research Workforce Turnover and Turbulence Study
Clinical research workforce movement and turnover can affect continuity, onboarding, and workload.
The calculator combines evidence from different studies and time periods. No cited source directly measures the complete national amount of research-site revenue that is unrealized because of enrollment workflow gaps.
Limitations and Privacy
What This Calculator Cannot Tell You
- It cannot predict whether a person will qualify for a study.
- It cannot predict whether a participant will consent or randomize.
- It cannot determine clinical eligibility.
- It cannot determine why every enrollment difference exists.
- It cannot calculate sponsor-level delayed product revenue.
- It cannot prove that every difference between current and attainable performance is recoverable.
- It cannot replace a protocol-specific site-budget analysis.
- It cannot guarantee that an operating investment will produce the modeled return.
- It does not calculate the complete cost of opening, maintaining, delaying, or closing a study.
- It should not be used for accounting, valuation, reimbursement, tax, or financial-reporting purposes.
- National scenarios are not measured national losses.
- The ClinicalTrials.gov total includes multiple study types and funding arrangements. It is not a count of commercially funded, randomized, or screening-payment-based research studies.
- The number of active U.S. site-protocol relationships is not directly reported in the ClinicalTrials.gov trend count.
- Screening and randomization contribution values vary by study.
- Users should replace all illustrative values with their own site and protocol information.
Enrollment performance may also be affected by protocol design, disease prevalence, eligibility criteria, competing trials, geography, investigator availability, participant preferences, sponsor decisions, study burden, and other factors outside early enrollment operations.
Privacy statement
Your calculator entries remain in your browser unless you choose to email the analysis. If you submit the email-analysis form, your contact information, calculator inputs, and results are sent to Consent2Randomize and emailed to you. Do not enter patient names, medical information, referral records, eligibility information, or protected health information into this calculator. Calculator data is not transmitted through URL query parameters, analytics event payloads, or third-party tracking scripts.
FAQ
Frequently Asked Questions
Next Step
Review Your Enrollment Revenue Estimate
Your estimate may point to gaps in follow-up, scheduling, attendance, documentation, or coordinator capacity. Review the assumptions with Consent2Randomize and identify which areas may be worth addressing.
Consent2Randomize supports early enrollment operations while the research site retains clinical judgment, eligibility decisions, informed consent, screening, randomization, participant care, and protocol oversight.